Over- and underreporting of seizures: How big is the problem?
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Patient seizure reporting accuracy is crucial for epilepsy management. This study found that while underreporting occurs, overreporting of non-epileptic events is also prevalent in ambulatory EEG monitoring.
Area Of Science
- Neurology
- Clinical Neurophysiology
Background
- Accurate seizure reporting is vital for epilepsy patient management.
- Discrepancies exist between patient-reported seizures and electroencephalographic (EEG) findings.
- Underreporting of seizures is recognized, but overreporting is less understood in large cohorts.
Purpose Of The Study
- To quantify the extent of seizure over- and underreporting in a large cohort of patients undergoing ambulatory EEG.
- To analyze the types of reported events (epileptic, psychogenic, non-correlated) in relation to EEG findings.
Main Methods
- Retrospective analysis of 3407 patients undergoing ambulatory video-EEG from 2020-2022.
- Classification of 21,024 recorded events as epileptic, psychogenic, or non-correlated events (NCEs).
- Analysis of events based on arousal state, referral indication, and epilepsy type (focal vs. generalized).
Main Results
- 27% of all events were epileptic seizures, with 64% of these underreported by patients.
- 58% of reported events were NCEs, more common in awake/drowsy states and various referral indications.
- NCEs were significantly higher in focal epilepsy (23%) compared to generalized epilepsy (10%).
Conclusions
- The study confirms underreporting and highlights significant overreporting of non-epileptic events in ambulatory EEG.
- Identifying NCEs is clinically relevant, potentially representing irrelevant symptoms or artifacts.
- Further research into risk factors and the etiology of NCEs is warranted.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Focal aware seizures: In these seizures, the person remains conscious...
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...